Masimo Outlines Ambitious Long-term Strategy with 7%-10% Revenue Growth and $8.00 EPS Target by 2028

Masimo, a healthcare technology company, hosted its 2025 Investor Day, outlining its long-term strategy through 2028. The company expects revenue growth of 7-10% CAGR, operating margin of 30% by 2028, adjusted EPS of $8.00 by 2028, and cumulative operating cash flow of $1 billion from 2026-2028. Masimo reaffirmed its 2025 financial guidance, projecting Non-GAAP revenue of $1.51-$1.53 billion, Non-GAAP operating profit of $412-$424 million, and Non-GAAP EPS of $5.40-$5.55.